Primary Esophageal Lymphoma: Clinical Experience in Diagnosis and Treatment

Junchi Qu 1, Yanyan Zhuang 2, Dandan Zheng 3, Fengting Huang 2, Shineng Zhang 2, 1

1. Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CHN
2. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CHN
3. Department of Gastroenterology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CHN

Corresponding author: Shineng Zhang, zhangshn@mail.sysu.edu.cn

Abstract

Primary esophageal lymphoma is a rare malignant tumor, which is often misdiagnosed. To improve the diagnosis and treatment of this disease, we presented one case admitted at our institution and a literature review of primary esophageal lymphoma cases, including the clinical data, features of imaging, endoscopy and pathology, treatment, and prognosis. The symptoms were non-specific. Under endoscopy, most of the lesions were located in the middle and lower segment of the esophagus, behaving as ulcers, polyps, or submucosal masses, always accompanying with esophageal stricture. The diagnosis of primary esophageal lymphoma was highly dependent on pathological and immunohistochemical examination, hence stacked sampling was suggested to improve the positive rate of mucosal biopsy. Combination of chemotherapy and radiotherapy may be the first choice of treatment, surgical and endoscopic resections may be an alternative solution as well. The therapeutic effect and prognosis were slightly better than those of other esophageal malignant tumors.

Introduction

Primary esophageal lymphoma is a rare malignant tumor. Most of the primary malignant tumors in the esophagus are squamous cell carcinoma (about 98%), rarely adenocarcinoma, sarcoma, and lymphoma. The digestive tract is the most frequently involved extranodal organ, accounting for about 10%-20% of lymphoma, which includes stomach (48%-50%), small intestine (30%-37%), and esophagus (1%) [1]. It is reported that most primary esophageal lymphoma occurs in patients over 50 years old, mostly in women [2]. However, the clinical manifestations of esophageal lymphoma are variable. Besides, the treatment approaches vary individually. However, an appropriate diagnosis and treatment strategy has not been established.

In this paper, the clinical data of 15 cases of primary esophageal lymphoma were collected and analyzed retrospectively, in which one case was admitted to our institution and 14 cases were reported in the literatures [2-14]. To improve the diagnosis and treatment of this disease, a systematic analysis was carried out, highlighting the clinical, endoscopic, and pathological features.

Materials And Methods

Patients and methods

We collected esophageal tumor specimens, imaging data, and endoscopic data of patients with primary esophageal lymphoma in Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University from January 1980 to December 2020. Only one patient was found in our hospital. The specimens were obtained through endoscopic biopsies with the informed consent of the patient before chemotherapy with histological confirmation. In addition, we searched PubMed, MEDLINE, and Web of Science databases for related articles published between January 1961 and December 2020 with the key words of "primary esophageal lymphoma" or "primary esophagus lymphoma." A total of 785 possible relevant literature reports were found and further selected according to the following inclusion and exclusion criteria after removing the duplicates. Inclusion criteria: 1. The lesion occurred in the esophagus. 2. The lesion was primary to the esophagus, not metastatic. 3. Histologically confirmed. Exclusion criteria: 1. Non-lymphomatous lesions. 2. Metastatic lesions to the esophagus. 3. Unable to obtain the necessary information for the case (such as endoscopy, CT, pathology, and immunohistochemical results). After being screened, 13 reports including a total of 14 patients with primary esophageal lymphoma were selected. The clinical characteristics of symptoms, endoscopic and imaging features were extracted from the articles (Figure 1)
Reports from the database PubMed, MEDLINE, and Web of Science (786)

Duplicates removed (270)

Reports screened (59)

Eligibility assessed (13)

Primary esophageal lesions, non-metastatic, and sufficient relevant information can be obtained

Reports screened by title and abstract

Reports included in this research (13)

FIGURE 1: The flowchart of literatures screening

An overview of the screening steps is presented as a flowchart.

---

Statistical analysis

Statistical analysis was carried out using SPSS version 25.0 software (SPSS, Inc., Chicago, IL, USA). Continuous variables were compared using analysis of variance, and were expressed as the mean ± standard deviation.

Results

Patients clinical characteristics

The median age of 15 patients with primary esophageal lymphoma was 57 years old (25-77 years), including 13 males (86.7%) and two females (13.3%). Of the 15 patients, one patient was asymptomatic (6.7%) and was diagnosed during a routine health checkup. Dysphagia was the most common symptom (12 patients, 80.0%), while other symptoms such as pharyngalgia (three patients, 20.0%), hematochezia (three patients, 20.0%), nausea, and vomiting (two patients, 13.3%) could also be observed. There was one patient (6.7%) with tracheoesophageal fistula. Unexpectedly, none of the patients had acid reflux or heartburn, the common symptoms in other esophageal illnesses (Table 1). The levels of digestive tract tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), and cancer antigen 19-9 (CA19-9), were within the normal range. The patient admitted to our hospital in November 2017 was a 25-year-old man suffering from dysphagia, nausea, vomiting, and pharyngalgia but denied acid reflux or heartburn (Table 1).
TABLE 1: Clinical features of the 15 patients with primary esophageal lymphoma

*Patient No.1 was treated in our hospital.
F: female; M: male; N: no; Y: yes

Image features

All patients underwent CT scan. Eight of them underwent additional enhanced CT. Generally, the CT manifestations of 15 patients with primary esophageal lymphoma were similar, while the endoscopic features were various. The tumors were all represented as low-density lesions on a plain CT scan, except two cases that were not described. Enhanced CT scan showed moderate and above enhancement of the lesions in five patients (62.5%) and mild enhancement in three patients (37.5%), among the eight patients who underwent enhanced CT scan. We also reported the enlargement of lymph nodes in the esophageal drainage area. A total of seven patients (46.7%) had local lymph node enlargement (all of them had enlarged mediastinal lymph nodes and two patients had hilar lymph node enlargement simultaneously). Interestingly, one patient had distant lymph nodes enlargement such as aortocaval lymph nodes and both common iliac lymph nodes without local lymph node enlargement (Table 2). The contrast-enhanced CT of the patient admitted to our institution showed an unclear boundary and low-density mass with mild heterogeneous enhancement in the middle part of the esophagus, around which enlarged and merged mediastinal lymph nodes could be observed, leading to esophageal stenosis (Figure 2).
| Patient No. | CT Density | Enhancement | Infiltration depth/cm | Lymphadenectomy | Site of tumor | Gross appearance | Mucosal erosion | Contact bleeding | Esophageal stricture |
|------------|------------|-------------|------------------------|------------------|--------------|-----------------|----------------|-----------------|-------------------|
| 1          | Low        | Mild heterogeneous enhancement | 47 | Mediastinal and hilar lymph nodes | M | Protruding and ulcerating | Y | Y | Y |
| 2          | Low        | Moderate-enhanced | ND | N | M | Ulcerating | Y | ND | Y |
| 3          | Low        | ND | Subcarinal lymph nodes | M | Multiple polyps | N | ND | N |
| 4          | Low        | ND | Paraortic lymph node | D | Protruding and circumferential ulcerating | Y | ND | Y |
| 5          | Low        | ND | Pretscheal, precarinal, and bilateral hilar lymph nodes | M-D | Circumferential ulcerating | ND | ND | Y |
| 6          | Low        | Poorly enhanced | ND | N | P | Polyps | Y | ND | Y |
| 7          | Low        | Weakly contrast-enhanced | 15 | Paraesophageal lymph nodes | P-D | Huge submucosal mass | N | N | N |
| 8          | Low        | ND | 2 | N | M-D | Infiltrating tumor | N | N | N |
| 9          | Low        | ND | 2 | N | M | Submucosal | N | N | N |
| 10         | Low        | Enhanced | ND | Mediastinal lymph nodes | M | Fungating and ulcerating | Y | Y | N |
| 11         | Low        | Mild contrast-enhanced | 15.5 | N | M-D | Lobulated submucosal mass | N | N | N |
| 12         | Low        | Enhanced | ND | N | M-D | Polyps and longitudinal ulcerating | Y | ND | Y |

**TABLE 2: Imaging and endoscopic features of the 15 patients with primary esophageal lymphoma**

ND: not described; N: no; Y: yes; P: proximal; M: middle; D: distal
FIGURE 2: Imaging characteristics of primary esophageal lymphoma

(A) CT revealing that the lesion was a low-density mass with obvious thickening of esophageal wall (red arrow) and stenosis of esophageal lumen (white arrow). (B) Contrast-enhanced CT revealing a mild heterogeneous enhanced lesion during the venous phase (white arrow). (C) Contrast-enhanced CT showing a mediastinal lymph node enlargement (black arrow), fusion with esophageal lesions, unclear boundary during the venous phase. (D) Contrast-enhanced CT showing a heterogeneous enhanced lesion during the arterial phase (white arrow).

Endoscopy manifestations

Endoscopic manifestations varied in 15 patients, including ulcerating (53.3%), polyps (26.7%), submucosal mass (26.7%), protruding (20.0%), fungating (6.7%), and infiltrating (6.7%). Most occurred in the middle and lower esophagus (11 patients, 73.3%), while in two patients (13.3%), occurred in the upper esophagus. In particular, one patient (7.1%) occurred in the upper and middle esophagus and another patient manifested as a huge submucosal mass that involved the whole segment of the esophagus. Furthermore, mucosal congestion and erosion were found in seven patients (46.7%), esophageal stricture in seven patients (46.7%), and contact bleeding in two patients (13.3%) (Table 2). The case treated in our hospital showed an infiltrative mass with obvious congestion and erosion in the mucosa, accompanying with obvious esophageal stricture (Figure 3).
FIGURE 3: Endoscopic features of primary esophageal lymphoma

(A) (B) Gastroscopy shows infiltrating masses in the middle part of the esophagus with erosion, ulcer, and significant lumen stenosis. (C) (D) Gastroscopy shows that the mass of esophagus is brittle and has contact bleeding.

Treatments and follow-up

Three patients underwent resection of the tumors. One patient underwent surgical procedure for the removal of the esophageal mass due to the misdiagnosis of leiomyoma by endoscopy. Two patients underwent endoscopic submucosal dissection (ESD), which manifested as oval or fusiform submucosal masses with clear boundary and soft texture. The other 12 patients underwent endoscopic forceps biopsy. The histopathology of 15 patients was B cell phenotype in 10 cases (66.7%) and T cell phenotype in five cases (33.3%). B cell phenotype included diffuse large B cell lymphoma (DLBL) (33.3%), mucosa-associated lymphoid tissue lymphoma (MALT) (33.3%), and small B cell lymphoma (6.7%), while T cell phenotype included natural killer (NK)/T cell lymphoma (13.3%), anaplastic large cell lymphoma (ALCL) (13.3%), and peripheral large T cell lymphoma (6.7%). Both phenotypes had lymphocyte-like cells infiltrate (Table 3). Histopathologically, diffuse distribution of lymphoid tumor cells with rich cytoplasm, large nucleus, and obvious atypia was microscopically found in the patient admitted in our hospital. The immunohistochemical features were CD30 (+), CD45 (+), leukocyte common antigen (LCA) (+), T-cell intracellular antigen-1 (TIA-1) (+), anaplastic lymphoma kinase (ALK) (+), Epstein-Barr virus-encoded RNAs (EBER) (-), which was in accordance with the characteristics of ALK-positive anaplastic large cell lymphoma (Figure 4).
| Patient No. | Gross appearance                  | Histopathology | IHC (positive) | FISH               | Treatment | Follow-up                  |
|------------|-----------------------------------|----------------|----------------|--------------------|-----------|---------------------------|
| 1          | Protruding and ulcerating         | ALCL           | CD30, CD43, LCA, TIA-1, ALK | EBER(−)           | C         | 2 years, no recurrence    |
| 2          | Ulcerating                        | DLBL           | LCA, CD20, CD79  | ND                 | S+C+R     | 16 months, no recurrence  |
| 3          | Multiple polyps                   | DLBL           | ND             | ND                 | Untreated | ND                        |
| 4          | Protruding and circumferential ulcerating | ALCL | CD30, CD3, ALK, MUM1 | t (2;5) translocation | C         | 13 months, complete remission |
| 5          | Circumferential ulcerating        | DLBL           | CD20, MIB-1/Ki67 98% | ND                 | R+C       | 3 years, disease free     |
| 6          | Polyps                             | NK/T cell      | CD3, CD56, Ki67 90%, TIA-1 | ND             | C         | 24 months, asymptomatic   |
| 7          | Huge submucosal mass              | MALT           | CD20, BCL-2    | MALT1-3/API2-2=16% | R         | 6 months, histological negativity |
| 8          | Infiltrating tumor                 | Small B cell   | CD20, CD10, CD79, BCL-2 | ND             | C         | 1 year, symptom relief    |
| 9          | Submucosal                         | MALT           | CD20, BCL-2    | ND                 | ESD       | 57 months, no recurrence  |
| 10         | Fungating and ulcerating          | DLBL           | CD20, CD10, CD45, CD79a, BCL-2 | ND       | C         | 6 months, partial remission |
| 11         | Lobulated submucosal mass         | MALT           | CD20, CD21, CD23, PAX-5, BCL-2 | EBER(−)       | S         | 8 months, asymptomatic and no recurrence |
| 12         | Polyps and longitudinal ulceration | NK/T cell      | CD2, CD3, CD43, CD8, CD56, TIA-1 | EBER(+)       | R+C       | 1 month, died of cerebral hemorrhage |
| 13         | Polyps and ulcerating             | Peripheral large T cell | T cells with loss of CD5 expression | ND       | C         | 10 months, disease free   |
| 14         | Subepithelial                      | MALT           | CD20, BCL-2, BCL-6, Ki67 5% | ND       | C         | 6 months, no recurrence   |
| 15         | Protruding and ulcerating         | DLBL           | CD79a, Mib-1     | ND                 | C         | 3 years, complete remission |

**TABLE 3: Pathological characteristics and treatment of the 15 patients with primary esophageal lymphoma**

IHC: immunohistochemistry; ALCL: anaplastic large cell lymphoma; DLBL: diffuse large B-cell lymphoma; MALT: mucosa-associated lymphoid tissue lymphoma; R: radiotherapy; C: chemotherapy; S: surgery; ESD: endoscopic submucosal dissection; ND: not described; LCA: leukocyte common antigen; TIA: T-cell intracellular antigen-1; ALK: anaplastic lymphoma kinase; EBERs: Epstein-Barr virus-encoded RNA
FIGURE 4: Pathological characteristics of primary esophageal lymphoma

(A) (B) Histopathology showed that lymphoid tumor cells were diffusely distributed, with large cells, rich cytoplasm, partially transparent, large nuclei, obvious atypia, and easy mitosis. All representative images shown are stained with hematoxylin and eosin; magnification: ×200.

In addition to one patient who refused treatment and follow-up, all the patients received individualized therapy. Eight patients received chemotherapy alone and two patients received radiotherapy combined with chemotherapy. One patient received radiotherapy alone. One patient underwent ESD and one patient underwent conventional surgery. Meanwhile, one patient received surgery combined with chemotherapy and radiotherapy. During the follow-up from half a year to one year, except for one patient who died of cerebral hemorrhage during treatment, there was no recurrence. The patient in our institution had a good prognosis after receiving eight courses of CHOP (Cyclophosphamide, Hydroxydaunorubicin—also known as doxorubicin, Oncovin—also known as vincristine, and Prednisone) chemotherapy. The primary tumor disappeared completely after therapy under endoscopy. Positron emission tomography-CT showed that there was no obvious abnormality in the whole esophagus and other parts of the body (Figure 5).

FIGURE 5: Follow-up of primary esophageal lymphoma after eight courses of CHOP regimen chemotherapy

(A) Gastroscopy showed that the original esophageal tumor disappeared completely, the mucous membrane of each segment of the esophagus was smooth, there was no ulcer and esophageal stricture. (B) PET-CT showed that there was no obvious abnormality in glucose metabolism in all segments of esophagus, no metastatic hypometabolic foci were found in paraesophageal lymph nodes, mediastinal lymph nodes, and other parts of the body, and no tumor recurrence and metastasis were found.

PET-CT: positron emission tomography-CT; CHOP: cyclophosphane, hydroxydaunorubicin, oncovin, and prednisone

Discussion

Primary esophageal lymphoma is very rare and a few cases have been reported worldwide. Dawson et al. concluded that the diagnostic criteria of primary esophageal lymphoma were as follows: 1. mainly involved esophagus; 2. only local lymph nodes were involved; no peripheral and mediastinal lymph nodes were involved; 3. normal liver and spleen; 4. normal granulocyte count [15]. However, 46.7% (7/15) of the patients in the study had enlarged mediastinal lymph nodes, histologically proved to be primary esophageal lymphoma. It seems that negative mediastinal lymph nodes are not necessary for the diagnosis of esophageal lymph nodes, which still needs to be further studied.
There are many difficulties in the clinical diagnosis of esophageal lymphoma. On the one hand, the clinical symptoms, endoscopic manifestations, and imaging features of esophageal lymphoma are variable, non-specific, and lack of specific markers, which often contribute to misdiagnosis. According to our study, primary esophageal lymphoma mainly manifests protruding mass with or without ulcer under endoscopy and dysphagia but no reflux or heartburn in clinical symptoms. And enhanced CT scan mainly shows uneven or relatively uniform mild to moderate enhancement. Patients with similar clinical manifestations as above may suggest the possibility of primary esophageal lymphoma. On the other hand, it is difficult to obtain ideal biopsy specimens because the main part of primary esophageal lymphoma often locates in the submucosa. The accurate diagnosis rates of endoscopy, percutaneous ultrasound, CT, and gastrointestinal barium meal were only 88.1%, 52%, 67%, and 83%, respectively [16]. With the low positive biopsy rate of the disease, clinicians should always take into account this disease when they encounter suspected patients. And taking stacked forceps biopsy which means repeated biopsies from the same lesion may help to avoid misdiagnosis [13].

There is no commonly acknowledged standard treatment for primary esophageal lymphoma. Chemotherapy, radiotherapy, surgery, and endoscopic resection are optional [17,18]. Recently, chemotherapy and radiotherapy are favorable and have become the first-line therapy, especially the CHOP regimen. There are different therapeutic options for different types of primary esophageal lymphoma. For instance, extranodal NK/T cell lymphoma is a highly invasive tumor with rapid progress and poor prognosis, a combination of radiotherapy and chemotherapy is of priority. And treatment scheme containing asparaginase is better than the conventional treatment schemes such as CHOP. With a total remission rate of 82.2% and a complete remission (CR) rate of 52.9%, Zhou et al. used DDGP (gemcitabine, pegaspargase, cisplatin, and dexamethasone) regimen to treat 17 patients with recurrent and refractory extranodal NK/T cell lymphoma [19]. Besides, the addition of rituximab to CHOP (R-CHOP) has proven to have higher response rates and improve the clinical outcome of patient with DLBL and R-CHOP [20]. Lee reported that cyclophosphamide, vincristine, and prednisolone (CVP) chemotherapy played a positive impact on MALT treatment [13]. Besides, MALT lymphoma is also sensitive to radiotherapy and 20-40 Gy is effective for tumor response and patient survival [21]. Once complications as obstruction, bleeding, or perforation occur, patients may need surgical intervention. Endoscopic esophageal dilatation or stent is alternative to treat stenosis [3]. Blystad et al. considered that bone marrow transplantation can be performed in the event of recurrence of esophageal lymphoma [22].

In summary, we put forth some new point of views of treatment and diagnosis in primary esophageal lymphoma. Partly consistent with Dawson, we propose the diagnostic criteria as follows: 1. The lesion mainly locates in the esophagus; 2. Only local and nearby lymph nodes (including mediastinal lymph nodes) are involved; no peripheral and distant ones are involved; 3. Without hepatosplenomegaly; 4. Mild to moderate enhancement of lesion under CT scan; 5. Normal tumor markers; 6. Pathologically confirmed. For the good response, chemotherapy alone is recommended for patients with B cell phenotype. For aggressiveness, combination therapy may be a better choice for patients with T cell phenotype. Surgery and ESD are suitable options for patients with a local lesion, absence of lymph nodes enlargement. However, because of the limited cases of primary esophageal lymphoma, these recommendations have limitations. Further validation of these findings may be necessary for future research.

Conclusions
The manifestations of primary esophageal lymphoma were non-specific. Thus, the diagnosis was highly dependent on pathological and immunohistochemical examination. Stacked sampling may be necessary to improve the positive rate. Combination of chemotherapy and radiotherapy may be the first choice of treatment, while surgical and endoscopic resections are also alternative solutions. The therapeutic effect and prognosis were slightly better than those of other esophageal malignant tumors.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Sun Yat-Sen Memorial Hospital ethics committee issued approval not applicable. The study has been approved by Sun Yat-Sen Memorial Hospital ethics committee. After obtaining the informed consent of the patient, the written informed consent of the participant in the study was collected. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements
This work was supported by grants from the National Natural Science Foundation of China (No. 81972004)
References

1. Ghimire P, Wu G-Y, Zhu L: Primary esophageal lymphoma in immunocompetent patients: two case reports and literature review. World J Radiol. 2010, 2:354-8. 10.4329/wjr.v2i8.334
2. Bolondi L, De Giorgio R, Santi V, et al.: Primary non-Hodgkin’s T-cell lymphoma of the esophagus. A case with peculiar endoscopic ultrasonographic pattern. Dig Dis Sci. 1990, 35:1426-30. 10.1007/BF01536752
3. Lino-Silva LS, Salcedo-Hernández RA, Molina-Frias E, et al.: Primary esophageal CD30-positive ALK-positive anaplastic large cell lymphoma with MUM1 expression. Esophagus. 2015, 10:51-4. 10.1007/s10388-012-0547-5
4. Sugore PT, Iwamuro S, Rekhi B, Karimundackal G, Purandare N, Pramesh CS: Isolated primary non-Hodgkin’s lymphoma of the esophagus. Indian J Med Paediatr Oncol. 2018, 39:244-6. 10.4103/ijmpo.ijmpo_131_17
5. Liang P, Ren X-C, Gao J-B: Radiological and clinical features of primary NK/T-cell lymphoma involving the whole length of the esophagus: a case report. Oncol Lett. 2017, 14:2147-52. 10.3892/ol.2017.6456
6. Kishi K, Maeda H, Nakamura Y, Shirai S, Sato M: Radiotherapy for mucosa-associated lymphoid tissue (MALT) lymphoma of the esophagus: a case report with a diagnostic and therapeutic discussion. Int J Clin Oncol. 2012, 17:174-80. 10.1007/s10147-011-0265-8
7. Zhu Q, Xu B, Xu K, Li J, Jin XL: Primary non-Hodgkin’s lymphoma in the esophagus. J Dig Dis. 2008, 9:241-4. 10.1111/j.1751-2980.2008.00554.x
8. Kobayashi S, Iwamuro M, Nishida K, et al.: Primary localized esophageal mucosa-associated lymphoid tissue lymphoma treated by endoscopic submucosal dissection. Intern Med. 2018, 57:3437-52. 10.2169/internalmedicine.0487-17
9. Teerakanok J, DeWitt JP, Juarez E, Thein KZ, Warraich I: Primary esophageal diffuse large B cell lymphoma presenting with tracheoesophageal fistula: a rare case and review. World J Gastrointest Oncol. 2017, 9:431-5. 10.4253/wjgo.v9.i10.431
10. Ma Q, Zhang C, Fang S, Zhong P, Zhu X, Lin L, Xiao H: Primary esophageal mucosa-associated lymphoid tissue lymphoma: a case report and review of literature. Medicine. 2017, 96:e4678. 10.1097/MD.0000000000006678
11. Ye ZY, Cao QH, Liu F, Lu XF, Li SR, Li CZ, Chen SH: Primary esophageal extranasal NK/T cell lymphoma with biphasic morphology: a case report and literature review. Medicine (Baltimore). 2015, 94:e1151. 10.1097/MD.000000000001151
12. Wagner PL, Tam W, Lau PY, Port JL, Paul S, Altorki NK, Lee PC: Primary esophageal large T-cell lymphoma mimicking esophageal carcinoma: a case report and literature review. J Thorac Cardiovasc Surg. 2008, 135:957-9. 958.e1. 10.1016/j.jtcs.2007.12.010
13. Lee DS, Ahn YC, Eom DW, Lee SJ: Primary esophageal mucosa-associated lymphoid tissue lymphoma diagnosed by using stacked forceps biopsy. Dis Esopha. 2016, 29:887-90. 10.1111/dote.12309
14. Park S, Jeen YT, Kwon YD, et al.: Successfully cured primary esophageal lymphoma in a patient with acquired immune deficiency syndrome (AIDS). Endoscopy. 2009, 41:E148-9. 10.1055/s-0029-119723
15. Dawson IM, Cormes JS, Morson BC: Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961, 49:80-9. 10.1002/bjs.1800492139
16. Sanchez-Bueno F, Garcia-Marcilla JA, Alonso JD, Acosta J, Carrasco L, Piñero A, Parrilla P: Prognostic factors in primary gastrointestinal non-Hodgkin’s lymphoma: a multivariate analysis of 76 cases. Eur J Surg. 1998, 164:585-92. 10.1007/BF01241587.50004427
17. Raderer M, Paul de Boer J: Role of chemotherapy in gastric MALT lymphoma, diffuse large B-cell lymphoma and other lymphomas. Best Pract Res Clin Gastroenterol. 2010, 24:19-26. 10.1016/j.bjp.2009.11.001
18. Choi J: Successful endoscopic resection of gastric mucosa-associated lymphoid tissue lymphoma unresponsive to Helicobacter pylori eradication therapy. Clin Endosc. 2020, 53:21-3. 10.5946/ce.2020.232
19. Zhou Z, Li X, Chen C, et al.: Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014, 93:1889-94. 10.1007/s00277-014-2156-7
20. Sharma B, Pavelock N, Antoine M, Shah M, Galbraith K, Rawlins S: Primary diffuse large B-cell lymphoma of the descending colon. Am J Med Sci. 2019, 358:164-7. 10.1016/j.amjms.2019.05.004
21. Sugimoto M, Kajimura M, Shirai N, et al.: Outcome of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy. Intern Med. 2006, 45:405-9. 10.2169/internalmedicine.45.1473
22. Blystad AK, Enblad G, Kvaløy S, et al.: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant. 2001, 27:711-6. 10.1038/sj.bmt.1702867